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In 2012, an outbreak of Neisseria meningitidis sero-
group W135 occurred in The Gambia. The attack rate was 
highest among young children. The associated risk factors 
were male sex, contact with meningitis patients, and difficult 
breathing. Enhanced surveillance facilitates early epidemic 
detection, and multiserogroup conjugate vaccine could re-
duce meningococcal epidemics in The Gambia.
Meningococcal disease is endemic to the African “meningitis belt”; outbreaks occur regularly (1,2). 
Neisseria meningitidis serogroup A causes most (80%) cas-
es. However, during 2002–2003, serogroup W135 caused 
a major epidemic in Burkina Faso (attack rate [AR] 251 
cases/100,000 population) (3). Thereafter, the incidence of 
serogroup W135 was low, with isolated cases and a small-
scale outbreak in the meningitis belt (4,5). In 2010, sero-
group A conjugate vaccine was introduced into the African 
meningitis belt and substantially reduced the incidence of 
meningitis (6).
In The Gambia, only 6 serogroup W135 cases were 
identified during 1990–1995; the most recent case had 
been reported in 1995 (7). In 2012, a large epidemic of 
serogroup W135 occurred throughout the meningitis belt, 
including The Gambia (1). Most risk factors identified in 
the meningitis belt concern serogroup A (8,9), and risk 
factors for serogroup W135 are little studied. Therefore, 
we report the investigation of this epidemic and the re-
lated risk factors.
The Study
The Gambian Ministry of Health and the Medical Re-
search Council Unit, The Gambia, investigated a serogroup 
W135 epidemic that occurred during February–June 2012 
in the Central River Region (CRR) and Upper River Re-
gion (URR). Since 2008, surveillance of invasive bacterial 
diseases has been ongoing in Bansang Hospital in CRR and 
Basse Health Centre in URR (10). The peripheral health 
centers refer severely ill patients to these health facilities. 
Three approaches were used to recruit persons with sus-
pected cases of serogroup W135: enhanced prospective 
surveillance in Bansang Hospital and Basse Health Cen-
tre, retrospective case identification from hospital records, 
and visits to households with confirmed case-patients se-
rogroup W135 to identify other suspected cases. A sus-
pected case was defined as a history of acute onset of fever 
and any of the following: altered consciousness, inability 
to eat, neck stiffness, seizures, petechial rash, or bulging 
anterior fontanel in a child <2 years of age. Cerebrospi-
nal fluid (CSF) and/or blood samples were collected from 
hospitalized persons with suspected serogroup W135. A 
confirmed case was a suspected case in which serogroup 
W135 was identified by culture and/or an antigen-specific 
test. The alert threshold was defined as >5 meningitis cases 
per 100,000 persons per week; the epidemic threshold was 
>10 cases (11).
The investigation team administered 1 dose of cipro-
floxacin to each close contact of confirmed case-patients 
and provided health information to raise awareness. At the 
end of the epidemic, The Gambian government deployed 
the tetravalent meningococcal polysaccharide vaccine.
CSF and blood samples were cultured for bacteria in 
BACTEC Medium (Becton Dickinson, Franklin Lakes, NJ, 
USA) and tested for serogrouping by latex agglutination 
by using BACTEC and Ramel (Thermo Fisher Scientific, 
Waltham, MA, USA) test kits. Antimicrobial drug suscep-
tibility was tested.
We conducted a matched case–control (ratio 1:1) study 
to identify risk factors. Healthy controls were matched by 
age and village with confirmed case-patients, including 
those who died. Demographic, socioeconomic, and expo-
sure (within 14 days before illness onset) data were collect-
ed by using a structured questionnaire. Risk factors were 
analyzed by conducting bivariate matched and multivariate 
conditional logistic regression analyses. The Joint Gambia 
Government/Medical Research Council Ethics Committee 
approved the study. All study participants or legal guard-
ians provided written informed consent.
During February 1–June 25, 2012, a total of 469 sus-
pected cases were identified, and 114 were confirmed to be 
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serogroup W135. Thirty-one were co-primary or secondary 
cases in confirmed case-patients’ households. Most (67%) 
suspected case-patients were <5 years of age, and 56% of 
cases occurred in male patients. The overall case-fatality 
rate was 8%.
The overall AR was 111 cases per 100,000 persons but 
was much higher among younger children (Table 1). The 
epidemic threshold was exceeded in the last week of Feb-
ruary and continued until April for persons of all ages and 
until June for children <5 years of age (Figure 1, panels 
A, B). Among children <5 years of age, the peak AR at-
tained 83 and 47 cases per 100,000 persons per week in 
CRR and URR, respectively (Figure 1, panel B). The epi-
demic peaked during the high temperature/driest months 
(March–May) and ended abruptly after the first rainfalls in 
June (Figure 2).
The most common signs and symptoms among the 113 
confirmed serogroup W135 case-patients were weakness 
(96%), irritability (88%), neck stiffness (81%), and inabil-
ity to eat (80%). Bulging fontanelle (74%), altered men-
tal status (73%), and seizures (65%) occurred in a slightly 
lower proportion of case-patients.
Blood and/or CSF samples were collected from 301 
(69%) of 438 hospitalized suspected case-patients, of 
which almost half (138) were positive for bacterial patho-
gens. Serogroup W135 was the major pathogen (114 [83%] 
of 138); followed by Streptococcus pneumoniae (13%) and 
Staphylococcus aureus (2%). Common antibacterial drugs 
used for meningitis were tested on 92 (81%) serogroup 
W135 isolates, which were susceptible to most of them 
(ampicillin, 100%; chloramphenicol, 99%; ciprofloxacin, 
99%; penicillin, 95%; and tetracycline, 92%) but not to 
erythromycin (59% susceptible) and trimethoprim/sulfa-
methoxazole (100% resistant).
We enrolled 106 confirmed case–control pairs. Risk 
factors identified in the univariate analysis were male sex, 
students, >4 children 1–5 years of age in the household, 
contact with a meningitis case-patient, preceding history 
of respiratory illness (nasal discharge, difficult breathing), 
and itchy eyes (Table 2, Appendix, wwwnc.cdc.gov/EID/
article/19/9/13-0077-T1.htm). In the multivariate analysis, 
male sex (odds ratio [OR] 1.9; 95% CI 1.0–3.7), contact 
with meningitis case-patients (OR 4.8; 95% CI 1.3–17.8), 
difficult breathing (OR 6.8; 95% CI 1.4–33.4), and itchy 
eyes (OR 4.4; 95% CI 1.3–14.4) remained significantly as-
sociated with cases.
Conclusions
Before the current cases, the most recent sporadic 
cases in The Gambia were reported in the early 1990s. 
These cases were part of a larger epidemic in the menin-
gitis belt with a comparable predominance of serogroup 
W135 followed by S. pneumoniae (1). After introduction of 
MenAfriVac (serogroup A conjugate vaccine), incidence 
and epidemics caused by serogroup A decreased substan-
tially in the meningitis belt (6,12). The reemergence of epi-
demic serogroup W135 in this region requires a strategy for 
surveillance, epidemic detection and control, and revised 
vaccination policy.
Serogroup A outbreaks usually affect children >5 
years of age and young adults (5,13,14). However, two 
thirds of the serogroup W135 cases occurred in children 
<5 years of age, for whom the AR was 5-fold higher than 
it was for older age groups, similar to the characteristics of 
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Table 1. Confirmed and suspected cases of Neisseria meningitidis serogroup W135, CRR and URR, The Gambia, February 1–June 
25, 2012* 
Health region/case-
patient age group, y Cases, no. (%) Deaths, no. (%) 2011 population† Cases/100,000 population 
CRR      <1 62 (20) 8 (13) 4,216 1,470 
 1–4 138 (45) 4 (3) 29,470 468 
 5–14 70 (23) 2 (3) 66,545 105 
 >15 37 (12) 4 (11) 115,995 32 
 Total 307 (100) 18 (6) 216,227 142 
URR 
     <1 47 (29) 10 (21) 4,086 1,150 
 1–4 70 (43) 5 (7) 27,564 254 
 5–14 36 (22) 2 (6) 64,014 56 
 >15 9 (6) 1 (11) 111,663 8 
 Total 162 (100) 18 (11) 207,327 78 
CRR and URR      <1 109 (23) 18 8,302 1,312 
 1–4 208 (44) 9 57,034 364 
 5–14 106 (23) 4 (4) 130,560 81 
 >15 46 (10) 5 (11) 227,658 20 
 Total 469 (100) 36 (8) 423,554 111 
*CRR, Central River Region; URR, Upper River Region. 
†Estimated on the basis of 2003 census. 
 
Meningococcal Disease, The Gambia
the serogroups W135 outbreaks in Burkina Faso (2002–
2003) and Niger (2010) (3,5). Therefore, the current oper-
ational definition of alert and epidemic thresholds, drawn 
mostly from serogroup A data, should be revised because 
merging the AR for all age groups may delay, or result in 
nondetection of, a serogroup W135 epidemic in younger 
age groups.
Signs and symptoms of concurrent respiratory illness 
were more prevalent among case-patients than controls;, 
itchy eyes and difficult breathing were associated with 
disease. The temporal sequence of these signs relative to 
the occurrence of meningococcal disease was not deter-
mined, and whether these factors facilitated the invasion 
of serogroup W135 carried in the nasopharynx or whether 
these symptoms were part of the initial serogroup W135 
infection before onset of severe disease is unclear. Con-
tact with confirmed serogroup W135 case-patients was 
a strong risk factor. These results are consistent with in-
formation available for the other serogroups and with the 
route of serogroup W135 transmission through droplet 
infection (15).
Our findings suggest that isolation of case-patients and 
prophylactic treatment of contacts may reduce transmission 
of meningococcal disease during epidemics. Enhanced sur-
veillance for meningitis is recommended for early detec-
tion of epidemics. The occurrence of this large serogroup 
W135 outbreak suggests that multiserogroup conjugate 
vaccine should be deployed for control and prevention.
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Figure 1. Outbreak of Neisseria 
meningitidis serogroup W135, 
Central River and Upper 
River Regions, The Gambia, 
February 1–June 25, 2012. 
A) Attack rate per 100,000 
persons per week. B) Attack 
rate per 100,000 children 
<5 years of age per week. 
Light gray bars, Central River 
Region; dark gray bars, Upper 
River Region. Alert threshold 
corresponds to an attack rate 
of 5; epidemic threshhold, to 
an attack rate of 10.
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Figure 2. Number of epidemic cases of Neisseria meningitidis serogroup W135 in relation to time, temperature, humidity, and rainfall, Central 
River Region, The Gambia, February 1–June 25, 2012. A color version of this figure is available online (wwwnc.cdc.gov/EID/article/19/09/13-
0077-F2.htm). 
